Used as a potent inhibitor of the sodium-glucose co-transporter 2 (SGLT2) in the treatment of type 2 diabetes. It helps lower blood glucose levels by promoting the excretion of excess glucose through urine. Due to its high selectivity for SGLT2, it minimizes the risk of off-target effects, making it suitable for long-term management of hyperglycemia. It also contributes to modest reductions in body weight and blood pressure, offering additional benefits in diabetic patients. The compound is typically administered orally and shows good bioavailability and metabolic stability. Its sulfinyl group enhances binding affinity and pharmacokinetic profile, supporting once-daily dosing in clinical settings.